Usage Trends: Molecular Diagnostic Platforms

March 2020 - Vol. 9 No. 3 - Page #19

This past November, MedicalLab Management published the results of our annual State of Laboratory Technology issue (, which included usage trends, satisfaction ratings, and acquisitions plans for several products in the clinical laboratory marketplace. Following are some additional results from this survey.

With clinical validity and utility remaining key to widespread molecular diagnostics implementations, the ongoing collaboration between clinical providers and laboratorians in determining both the appropriateness of molecular testing and, perhaps more important, the interpretation of the results of that testing, is essential to the promise of personalized medicine. As technological advances in molecular diagnostics continue with the exciting use of nucleic acid-based amplification technologies (NAATs) and polymerase chain reaction (PCR), digital PCR, and next generation sequencing (NGS), clinical laboratories will benefit from rapid translation of established and emerging molecular tests.

Implementations of molecular diagnostic platforms will continue apace, with 66% of planned adoptions forecasted to take place within the next 3 years.

Molecular diagnostics enjoys particularly strong satisfaction with a fulsome 89% rating their vendors as excellent or good.

Both BioFire and Cepheid are well represented here among vendors under consideration, with bioMérieux, BD, Luminex, and others receiving substantial consideration as well.

Click here to view a larger version of this Figure


Like what you've read? Please log in or create a free account to enjoy more of what has to offer.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: